Business · 26/05/2022Updated: 10/17/2026 · 1 min read
Gilead Sciences Withdraws FDA Approval for ZYDELIG Indications for Relapsed Lymphoma
Summary
Gilead Sciences, Inc. has voluntarily withdrawn FDA approval for ZYDELIG (idelalisib) Tablets to treat relapsed follicular lymphoma and relapsed small lymphocytic lymphoma, following a request to the FDA.